52 related articles for article (PubMed ID: 36656832)
21. Simplified Test-to-Treat Strategy for Hepatitis C in Thailand: The Phetchabun Model.
Wasitthankasem R; Wanlapakorn N; Pimsing N; Posuwan N; Poovorawan Y
J Infect Dis; 2023 Sep; 228(Suppl 3):S198-S203. PubMed ID: 37703343
[TBL] [Abstract][Full Text] [Related]
22. Multicenter Evaluation of the Cepheid Xpert Hepatitis C Virus Viral Load Assay.
McHugh MP; Wu AHB; Chevaliez S; Pawlotsky JM; Hallin M; Templeton KE
J Clin Microbiol; 2017 May; 55(5):1550-1556. PubMed ID: 28275079
[TBL] [Abstract][Full Text] [Related]
23. Prescreening with a Rapid Diagnostic Test Followed by a Confirmatory Qualitative Nucleic Acid Test Can Simplify Hepatitis C Diagnosis.
Wasitthankasem R; Posuwan N; Pimsingh N; Phaengkha W; Ngamnimit S; Vichaiwattana P; Thongpan I; Tongsima S; Vongpunsawad S; Poovorawan Y
Am J Trop Med Hyg; 2022 Feb; 106(5):1534-8. PubMed ID: 35226876
[TBL] [Abstract][Full Text] [Related]
24. Real-world efficacy and safety of pangenotypic direct-acting antivirals against hepatitis C virus infection in Taiwan.
Chang KC; Tung SY; Wei KL; Shen CH; Hsieh YY; Chen WM; Chen YH; Chen CH; Yen CW; Xu HW; Tung WL; Hung CH; Lu SN; Chang TS
Sci Rep; 2021 Jun; 11(1):13543. PubMed ID: 34188161
[TBL] [Abstract][Full Text] [Related]
25. Epidemiology of hepatitis C virus infection.
Roudot-Thoraval F
Clin Res Hepatol Gastroenterol; 2021 May; 45(3):101596. PubMed ID: 33610022
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of Hepatitis C Virus in an Endemic Area of Thailand: Burden Assessment toward HCV Elimination.
Wasitthankasem R; Pimsingh N; Treesun K; Posuwan N; Vichaiwattana P; Auphimai C; Thongpan I; Tongsima S; Vongpunsawad S; Poovorawan Y
Am J Trop Med Hyg; 2020 Jul; 103(1):175-182. PubMed ID: 32394881
[TBL] [Abstract][Full Text] [Related]
27. Global elimination of hepatitis C virus by 2030: why not?
Dore GJ; Martinello M; Alavi M; Grebely J
Nat Med; 2020 Feb; 26(2):157-160. PubMed ID: 32047317
[No Abstract] [Full Text] [Related]
28. Hepatitis C.
Spearman CW; Dusheiko GM; Hellard M; Sonderup M
Lancet; 2019 Oct; 394(10207):1451-1466. PubMed ID: 31631857
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Virus: Part 1 of the DORA Study.
Jonas MM; Squires RH; Rhee SM; Lin CW; Bessho K; Feiterna-Sperling C; Hierro L; Kelly D; Ling SC; Strokova T; Del Valle-Segarra A; Lovell S; Liu W; Ng TI; Porcalla A; Gonzalez YS; Burroughs M; Sokal E
Hepatology; 2020 Feb; 71(2):456-462. PubMed ID: 31254392
[TBL] [Abstract][Full Text] [Related]
30. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
[TBL] [Abstract][Full Text] [Related]
31. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.
Wyles D; Poordad F; Wang S; Alric L; Felizarta F; Kwo PY; Maliakkal B; Agarwal K; Hassanein T; Weilert F; Lee SS; Kort J; Lovell SS; Liu R; Lin CW; Pilot-Matias T; Krishnan P; Mensa FJ
Hepatology; 2018 Feb; 67(2):514-523. PubMed ID: 28926120
[TBL] [Abstract][Full Text] [Related]
32. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.
Forns X; Lee SS; Valdes J; Lens S; Ghalib R; Aguilar H; Felizarta F; Hassanein T; Hinrichsen H; Rincon D; Morillas R; Zeuzem S; Horsmans Y; Nelson DR; Yu Y; Krishnan P; Lin CW; Kort JJ; Mensa FJ
Lancet Infect Dis; 2017 Oct; 17(10):1062-1068. PubMed ID: 28818546
[TBL] [Abstract][Full Text] [Related]
33. Assessment of hepatitis C virus infection in two adjacent Thai provinces with drastically different seroprevalence.
Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thaneskongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Suwanpatoomlerd S; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Vongpunsawad S; Poovorawan Y
PLoS One; 2017; 12(5):e0177022. PubMed ID: 28475637
[TBL] [Abstract][Full Text] [Related]
34. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.
Polaris Observatory HCV Collaborators
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):161-176. PubMed ID: 28404132
[TBL] [Abstract][Full Text] [Related]
35. Decreasing Hepatitis C Virus Infection in Thailand in the Past Decade: Evidence from the 2014 National Survey.
Wasitthankasem R; Posuwan N; Vichaiwattana P; Theamboonlers A; Klinfueng S; Vuthitanachot V; Thanetkongtong N; Saelao S; Foonoi M; Fakthongyoo A; Makaroon J; Srisingh K; Asawarachun D; Owatanapanich S; Wutthiratkowit N; Tohtubtiang K; Yoocharoen P; Vongpunsawad S; Poovorawan Y
PLoS One; 2016; 11(2):e0149362. PubMed ID: 26871561
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis and management of hepatitis C.
Vine LJ; Sieberhagen C; Cramp ME
Br J Hosp Med (Lond); 2015 Nov; 76(11):625-30. PubMed ID: 26551491
[TBL] [Abstract][Full Text] [Related]
37. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.
Denniston MM; Jiles RB; Drobeniuc J; Klevens RM; Ward JW; McQuillan GM; Holmberg SD
Ann Intern Med; 2014 Mar; 160(5):293-300. PubMed ID: 24737271
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
